R. Siegel and D. Naishadham, Cancer statistics, 2012, CA: A Cancer Journal for Clinicians, vol.287, issue.suppl 5, pp.10-29, 2012.
DOI : 10.3322/caac.20138

J. Isaacs and W. Isaacs, Androgen receptor outwits prostate cancer drugs, Nature Medicine, vol.10, issue.1, pp.26-27, 2004.
DOI : 10.1038/nm0104-26

S. Denmeade and J. Isaacs, A history of prostate cancer treatment, 2002.

F. Saad, C. Sternberg, and S. Tagawa, New therapies for, 2011.

B. Feldman and D. Feldman, The development of androgen-independent prostate cancer, Nature Reviews Cancer, vol.1, issue.1, pp.34-45, 2001.
DOI : 10.1038/35094009

O. Dorai, T. Buttyan, and R. , Transdifferentiation of prostate cancer cells to &+'" a neuroendocrine cell phenotype in vitro and in vivo, The Journal of urology, vol.162, pp.1800-1805, 1999.

M. Wright, M. Tsai, and R. Aebersold, Androgen Receptor Represses the Neuroendocrine Transdifferentiation Process in Prostate Cancer Cells, Molecular Endocrinology, vol.17, issue.9, pp.1726-1737, 2003.
DOI : 10.1210/me.2003-0031

T. Yuan, S. Veeramani, F. Lin, D. Kondrikou, S. Zelivianski et al., Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells, Endocrine Related Cancer, vol.13, issue.1, 2006.
DOI : 10.1677/erc.1.01043

C. Sauer, A. Roemer, and R. Grobholz, Genetic analysis of neuroendocrine tumor cells in prostatic carcinoma, The Prostate, vol.277, issue.3, pp.227-234, 2006.
DOI : 10.1002/pros.20338

T. Jiborn, A. Bjartell, and P. Abrahamsson, Neuroendocrine Differentiation in Prostatic Carcinoma During Hormonal Treatment, Urology, vol.51, issue.4, pp.585-589, 1998.
DOI : 10.1016/S0090-4295(97)00684-5

R. Friedman, M. Burchardt, D. Chopin, and R. Buttyan, The emergence of &#(" protocadherin-PC expression during the acquisition of apoptosis-resistance by &#)" prostate cancer cells, Oncogene, vol.21, pp.7861-7871, 2002.

M. Benson, Y. Guo, and R. Buttyan, A human-and male-specific &$%" protocadherin that acts through the wnt signaling pathway to induce &$&" neuroendocrine transdifferentiation of prostate cancer cells, Cancer research, vol.65, pp.5263-5271, 2005.
URL : https://hal.archives-ouvertes.fr/inserm-00106398

E. Murphy and G. , LNCaP model of human prostatic carcinoma, Cancer &$, vol.43, pp.1809-1818, 1983.

P. Tran, C. Abbou, R. Buttyan, and F. Vacherot, Protocadherin-PC &%#" promotes androgen-independent prostate cancer cell growth. The Prostate 66, pp.1100-1113, 2006.
URL : https://hal.archives-ouvertes.fr/inserm-00106397

K. Cleutjens, H. Van-der-korput, C. Van-eekelen, H. Van-rooij, P. Faber et al., An Androgen Response Element in a Far Upstream Enhancer Region Is Essential for High, Androgen-Regulated Activity of the Prostate-Specific Antigen Promoter, Molecular Endocrinology, vol.11, issue.2, pp.148-161, 1997.
DOI : 10.1210/mend.11.2.9883

J. Romijn, C. Verkoelen, and F. Schroeder, Application of the MTT assay to human prostate cancer cell lines in vitro: Establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects, The Prostate, vol.5, issue.1, pp.99-110, 1988.
DOI : 10.1002/pros.2990120112

H. Beltran, D. Rickman, K. Park, S. Chae, A. Sboner et al., Molecular characterization of &&%" neuroendocrine prostate cancer and identification of new drug targets, Cancer &&&, vol.1, pp.487-495, 2011.

L. Kheuang, E. Coppolani, A. Ali, and F. Bibeau, Increased expression of &&)" class III beta-tubulin in castration-resistant human prostate cancer, British journal &&*, vol.101, pp.951-956, 2009.

G. Van-steenbrugge, C. Van-uffelen, J. Bolt, and F. Schroder, The &'!" human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model &'#" for the study of androgen sensitivity. The Journal of steroid biochemistry and, pp.207-214, 1991.

D. Bernard, A. Pourtier-manzanedo, J. Gil, and D. Beach, Myc confers &')" androgen-independent prostate cancer cell growth. The Journal of clinical, pp.1724-1731, 2003.

J. Veldscholte, C. Berrevoets, C. Ris-stalpers, G. Kuiper, G. Jenster et al., The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens, The Journal of Steroid Biochemistry and Molecular Biology, vol.41, issue.3-8, pp.665-669, 1992.
DOI : 10.1016/0960-0760(92)90401-4

D. Masiello, S. Cheng, G. Bubley, M. Lu, and S. Balk, Bicalutamide Functions as an Androgen Receptor Antagonist by Assembly of a Transcriptionally Inactive Receptor, Journal of Biological Chemistry, vol.277, issue.29, pp.26321-26326, 2002.
DOI : 10.1074/jbc.M203310200

X. Yang, M. Chen, S. Terry, F. Vacherot, D. Bemis et al., Complex regulation of human &), p.26, 2006.

S. Marengo, J. Rhim, D. Zhang, and J. Jacobberger, A new human &)(" prostate carcinoma cell line, 22Rv1, In Vitro Cell Dev Biol Anim, vol.35, pp.403-409, 1999.

S. Denmeade, L. Sokoll, S. Dalrymple, D. Rosen, A. Gady et al., Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models, The Prostate, vol.62, issue.4, pp.249-257, 2003.
DOI : 10.1002/pros.10199

D. Frigo and D. Mcdonnell, Differential effects of prostate cancer '++" therapeutics on neuroendocrine transdifferentiation. Molecular cancer, pp.659-669, 2008.

M. Day, X. Zhao, S. Wu, P. Swanson, and P. Humphrey, Phorbol ester- '+$" induced apoptosis is accompanied by NGFI-A and c-fos activation in androgen- '+%" sensitive prostate cancer cells, Cell Growth Differ, vol.5, pp.735-741, 1994.

Y. Akao, S. Kusakabe, Y. Banno, M. Kito, Y. Nakagawa et al., Ceramide accumulation is '+(" 27 independent of camptothecin-induced apoptosis in prostate cancer LNCaP cells, pp.363-370, 2002.

R. Shah, R. Mehra, A. Chinnaiyan, R. Shen, D. Ghosh et al., Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases: Lessons from a Rapid Autopsy Program, Cancer Research, vol.64, issue.24, pp.9209-9216, 2004.
DOI : 10.1158/0008-5472.CAN-04-2442

L. Wafa, J. Palmer, L. Fazli, A. Hurtado-coll, R. Bell et al., Comprehensive expression analysis of l-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors, Human Pathology, vol.38, issue.1, pp.161-170, 2007.
DOI : 10.1016/j.humpath.2006.07.003

H. Bonkhoff, U. Stein, and K. Remberger, Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells*1, Human Pathology, vol.26, issue.2, pp.167-170, 1995.
DOI : 10.1016/0046-8177(95)90033-0

R. Berges, J. Vukanovic, J. Epstein, M. Carmichel, L. Cisek et al., Implication of cell kinetic changes during '#'" the progression of human prostatic cancer. Clinical cancer research : an official '#, journal of the American Association for Cancer Research, vol.1, pp.473-480, 1995.

C. Chen, D. Welsbie, C. Tran, S. Baek, R. Chen et al., Molecular determinants of resistance to antiandrogen therapy, Nature Medicine, vol.10, issue.1, pp.33-39, 2004.
DOI : 10.1038/nm972

C. Heinlein and C. C. , Androgen Receptor in Prostate Cancer, Endocrine Reviews, vol.25, issue.2, 2004.
DOI : 10.1210/er.2002-0032

D. Klimstra, I. Modlin, N. Adsay, R. Chetty, V. Deshpande et al., Pathology reporting of '$&" neuroendocrine tumors: application of the Delphic consensus process to the '$'" development of a minimum pathology data set. The American journal of surgical '$, pp.300-313, 2010.

B. Helpap and J. Kollermann, Immunohistochemical analysis of the '$*" proliferative activity of neuroendocrine tumors from various organs. Are there '%+" indications for a neuroendocrine tumor-carcinoma sequence? Virchows Archiv, pp.86-91, 2001.

W. Wang and J. Epstein, Small cell carcinoma of the prostate. A '%$" morphologic and immunohistochemical study of 95 cases. The American journal, pp.65-71, 2008.

S. Sun, C. Sprenger, R. Vessella, K. Haugk, K. Soriano et al., Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant, Journal of Clinical Investigation, vol.120, issue.8, pp.2715-2730, 2010.
DOI : 10.1172/JCI41824DS1

R. Hu, T. Dunn, S. Wei, S. Isharwal, R. Veltri et al., Ligand-independent androgen receptor, p.29, 2009.

J. Yu, J. Yu, R. Mani, Q. Cao, C. Brenner et al., An integrated network of androgen receptor, polycomb, and '&*" TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer cell 17, pp.443-454, 2010.

B. Carver, C. Chapinski, J. Wongvipat, H. Hieronymus, Y. Chen et al., Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer, Cancer Cell, vol.19, issue.5, pp.575-586, 2011.
DOI : 10.1016/j.ccr.2011.04.008

S. Kasper and R. Matusik, NE-10 neuroendocrine cancer promotes the ''(" LNCaP xenograft growth in castrated mice, Cancer research, vol.64, pp.5489-5495, 2004.

P. Gene, Cultures of LNCaP cells were ')*" grown 24 hrs in 10% CS-FBS media supplemented or not with incremental doses of '*+" DHT. RT-PCR analysis for PCDH-PC (Left) and KLK3 (right) levels in DHT-treated over '*!" vehicle treated. (B) LNCaP cells were grown for 72h in 5% CS-FBS media then '*#" refreshed with media supplemented with 100nM DHT, and PCDH-PC as well as KLK3 '*$" levels inspected as the indicated time. (C) LNCaP cells were grown in 10% FBS in the '*%" presence or absence of bicalutamide 10 µmol/L for 10 days and mRNA levels for PCDH, Figure 2 Androgenic regulation of PC and KLK3 examined. (D) Histograms showing normalized levels of KLK2 (left), KLK3 '*'" (middle), PCDH-PC (right) from LNCaP-AI cultures treated with bicalutamide for 8 days

. Lncap-ai, 5 nmol/L docetaxel. Bars, means ± SEM of two '**" independent experiments done in triplicate. (F) Morphology of LNCaP-AI cells